COLL vs. MIRM, MNKD, PCRX, SYRE, VRNA, ABCL, BLTE, PRTA, GYRE, and IRWD
Should you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Mirum Pharmaceuticals (MIRM), MannKind (MNKD), Pacira BioSciences (PCRX), Spyre Therapeutics (SYRE), Verona Pharma (VRNA), AbCellera Biologics (ABCL), Belite Bio (BLTE), Prothena (PRTA), Gyre Therapeutics (GYRE), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.
Collegium Pharmaceutical (NASDAQ:COLL) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.
Collegium Pharmaceutical has a net margin of 8.50% compared to Mirum Pharmaceuticals' net margin of -86.33%. Collegium Pharmaceutical's return on equity of 107.39% beat Mirum Pharmaceuticals' return on equity.
Collegium Pharmaceutical currently has a consensus price target of $39.00, suggesting a potential upside of 2.90%. Mirum Pharmaceuticals has a consensus price target of $52.20, suggesting a potential upside of 99.08%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Collegium Pharmaceutical.
Collegium Pharmaceutical has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Collegium Pharmaceutical received 269 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 71.81% of users gave Mirum Pharmaceuticals an outperform vote while only 65.39% of users gave Collegium Pharmaceutical an outperform vote.
In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 7 mentions for Collegium Pharmaceutical. Mirum Pharmaceuticals' average media sentiment score of 0.51 beat Collegium Pharmaceutical's score of 0.46 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.
Collegium Pharmaceutical has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
Summary
Mirum Pharmaceuticals beats Collegium Pharmaceutical on 9 of the 17 factors compared between the two stocks.
Get Collegium Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Collegium Pharmaceutical Competitors List
Related Companies and Tools
